Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors

Emerging Therapies, Web Exclusives

Coming soon…
Symptom Management, Web Exclusives - January 16, 2019

Targeted Intervention Reduces Opioid Use by Nearly 50% After Urologic Oncology Surgery

Patients can be successfully managed with minimal opioid medication after urologic oncology surgery, said Kerri Stevenson, MN, NP-C, RNFA, CWOCN, Lead Advanced Practice Provider – Interventional Radiology, Stanford Health Care, CA, at the 2018 ASCO Quality Care Symposium. She presented results from a 4-month study conducted at Stanford Health Care. Over the course of the study, patients were able to decrease their opioid use after surgery by 46%, without compromising pain control.

Web Exclusives - October 15, 2019

FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments

FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.